• 1
    Simons FE & Simons KJ. The pharmacology and use of H1-receptor-antagonist drugs. N Engl J Med 1994; 330: 16631670.
  • 2
    Goldberg MJ, Spector R, Chiang CK. Transport of diphenhydramine in the central nervous system. J Pharmacol Exp Ther 1987; 240: 717722.
  • 3
    Yanai K, Okamura N, Tagawa M, Itoh M, Watanabe T. New findings in pharmacological effects induced by antihistamines: from PET studies to knock-out mice. Clin Exp Allergy 1999; 29(Suppl 3): 2936.
  • 4
    Okamura N, Yanai K, Higuchi M, et al. Functional neuroimaging of cognition impaired by a classical antihistamine, d-chlorpheniramine. Br J Pharmacol 2000; 129: 115123.
  • 5
    Luria X. Comparative clinical studies with ebastine, efficacy and tolerability. Drug Saf 1999; 21(Suppl 1): 6367.
  • 6
    De Molina M, Cadahia L, Cano L, et al. Efficacy and tolerability of ebastine at two dose levels in the treatment of seasonal allergic rhinitis. Drug Invest 1989; 1: 4046.
  • 7
    Gehannol P, Brémard-Oury C, Zeisser P. A double-blind multicenter randomized study comparing once daily oral administration of ebastine 20 mg, ebastine 10 mg, and cetirizine 10 mg for the treatment of seasonal allergic rhinitis in adults. Rhône-Poulenc Rorer (Collegeville). (Data on file).
  • 8
    Picado VC, Cadahia GA, Cistero BA, Cano CL, Sanz AA, Zayas SJM. Ebastine in perennial allergic rhinitis. Ann Allergy 1991; 67: 615618.
  • 9
    Baba S, Mamiya S, Sakakura Y, et al. Clinical trial of LAS-90 on perennial allergic rhinitis: a double blind study in comparison with ketotifen fumarate [in Japanese]. Rinsho Iyaku 1994; 10: 11431162.
  • 10
    Kalis B & Brémard-Oury C. A 3-month double-blind comparative study of ebastine (10 mg o.d.), terfenadine (60 mg b.i.d.) and placebo in the treatment of chronic urticaria. Allergy 1995; 50(Suppl): 380.
  • 11
    Peyri J, Vidal J, Marrón J, et al. Ebastine in chronic urticaria: a double-blind placebo-controlled study. J Dermatol Treat 1991; 2: 5153.
  • 12
    Yamaguchi T, Hashizume T, Matsuda M, et al. Pharmacokinetics of the H1-receptor antagonist ebastine and its active metabolite carebastine in healthy subjects. Arzneimittelforschung Drug Res 1994; 44: 5964.
  • 13
    Vincent J, Liminana R, Meredith PA, Reid JL. The pharmacokinetics, antihistamine and concentration-effect relationship of ebastine in healthy subjects. Br J Clin Pharmacol 1988; 26: 497502.
  • 14
    Fujii T, Matsumoto S, Amejima H, et al. Absorption, distribution, metabolism and excretion of [14C]ebastine after a single administration in rats. Arzneimittelforschung Drug Res 1994; 44: 527538.
  • 15
    Tagawa M, Kano M, Okamura N, et al. Differential cognitive effects of ebastine and (+)-chlorpheniramine in healthy subjects: Correlation between cognitive impairment and plasma drug concentration. Br J Clin Pharmacol (in press).
  • 16
    Kukita A, Harada S, Yoshida H, et al. Phase III study of LAS-90 on chronic urticaria: double blind comparative study with ketotifen fumarate [in Japanese]. Rinsho Iyaku 1994; 10: 895912.
  • 17
    Fujiwara T, Watanuki S, Yamamoto S et al. Performance evaluation of a large axial field-of-view PET scanner SET-2400W. Ann Nucl Med 1997; 11: 307313.
  • 18
    Spinks TJ, Guzzardi R, Bellina CR. Performance characteristics of a whole body positron tomograph. J Nucl Med 1988; 29: 18331841.
  • 19
    Yanai K, Watanabe T, Yokoyama H, et al. Histamine H1 receptors in human brain visualized in vivo by [11C]doxepin and positron emission tomography. Neurosci Lett 1992; 137: 145148.
  • 20
    Yanai K, Ryu JH, Watanabe T, et al. Histamine H1 receptor occupancy in human brains after single oral doses of histamine H1 antagonists measured by positron emission tomography. Br J Pharmacol 1995; 116: 16491655.
  • 21
    Logan J, Fowler JS, Volkow ND, et al. Graphical analysis of reversible radioligand binding form time-activity measurements applied to [N-11C-methyl]-(−)-cocaine PET studies in human subjects. J Cereb Blood Flow Metab 1990; 10: 740747.
  • 22
    Friston KJ, Holmes AP, Worsley KJ, Poline JP, Frith CD, Frackowiak RSJ. Statistical parametric maps in functional imaging: a general linear approach. Human Brain Mapping 1995; 2: 189210.
  • 23
    Higuchi M, Yanai K, Okamura N, et al. Histamine H1 receptors in patients with Alzheimer's disease assessed by positron emission tomography (PET). Neuroscience 2000; 99: 721729.
  • 24
    Higuchi M, Itoh M, Yanai K, et al. Brain mapping of the effects of aging on histamine H1 receptors in humans: A PET study with [11C]-doxepin. In Quantitative functional brain imaging with positron emission tomography, eds. CarsonR, Daube-WitherspoonM, HerscovitchP. San Diego: Academic Press, 1998; Chapter 31: 207214.
  • 25
    Talairach J & Tournoux P. Co-Planar Stereotaxic Atlas of the Human Brain. New York: Thieme. Medical Publishers, Inc. 1988.
  • 26
    Peets EA, Jackson M, Symchowicz S. Metabolism of chlorpheniramine maleate in man. J Pharmacol Exp Ther 1972; 180: 464474.
  • 27
    Hiep BT, Gimenez F, Khanh VU, et al. Binding of chlorpheniramine enantiomers to human plasma proteins. Chirality 1999; 11: 501504.
  • 28
    Chang RS, Tran VT, Snyder SH. Heterogeneity of histamine H1-receptors: species variations in [3H]mepyramine binding of brain membranes. J Neurochem 1979; 32: 16531663.
  • 29
    Arias-Montano JA & Young JM. Characteristics of histamine H1 receptors on HeLa cells. Eur J Pharmacol 1993; 245: 291295.
  • 30
    Yamashita M, Fukui H, Sugama K, et al. Expression cloning of a cDNA encoding the bovine histamine H1 receptor. Proc Natl Acad Sci USA 1991; 88: 1151511519.
  • 31
    Ter Laak AM, Donne-Op den Kelder GM, Bast A, Timmerman H. Is there a difference in the affinity of histamine H1 receptor antagonists for CNS and peripheral receptors? An in vitro study. Eur J Pharmacol 1993; 232: 199205.
  • 32
    Inoue I, Yanai K, Kitamura D, et al. Impaired locomotor activity and exploratory behaviour in mice lacking histamine H1 receptors. Proc Natl Acad Sci USA 1996; 93: 1331613320.DOI: 10.1073/pnas.93.23.13316
  • 33
    Rose C, Quach TT, Llorens C, Schwartz JC. Relationship between occupation of cerebral H1-receptors and sedative properties of antihistamines. Assessment in the case of terfenadine. Arzneim-Forsch/Drug Res 1982; 32: 11711173.
  • 34
    Yanai K, Ryu JH, Watanabe T, et al. Positron emission tomographic study of central histamine H1-receptor occupancy in human subjects treated with epinastine, a second-generation antihistamine. Meth Find Exp Clin Pharmacol 1995; 17(Suppl C): 6469.
  • 35
    Tamai I, Kido Y, Yamashita J, Sai Y, Tsuji A. Blood–brain barrier transport of H1-antagonist ebastine and its metabolite carebastine. J Drug Targeting 2000; 8: 383393.